Biosimilar Antibodies

Amostomig is a humanized IgG1λ2 monoclonal antibody designed to specifically target CD274 and CD47. For experimental control purposes, the recommended isotype control is Human IgG1 lambda2.

Pegacaristim is a monoclonal antibody designed to exhibit thrombopoietic activity, effectively stimulating the production of platelets. This targeted biological mechanism positions Pegacaristim as a crucial tool in research focused on hematopoiesis and the therapeutic management of conditions associated with thrombocytopenia.

Vanutide cridificar (ACC-001) is a conjugate of the aminoterminal Aβ1-7 peptide. This biologic is specifically designed for use in Alzheimer's disease (AD) research, facilitating the study of amyloid-beta dynamics and pathology in neurodegenerative processes. Its application in experimental models provides a valuable tool for advancing our understanding of AD mechanisms and potential therapeutic targets.

Pinatuzumab is a monoclonal antibody specifically targeting the cell-surface antigen CD22. This antibody is employed primarily in the development of antibody-drug conjugates (ADCs) for the investigation of various diseases, notably non-Hodgkin lymphoma (NHL). Pinatuzumab's specificity for CD22 makes it a valuable tool in research focused on hematological malignancies.

Linavonkibart (SRK 181) is a fully human monoclonal antibody engineered to exhibit high affinity for latent TGFβ1, effectively inhibiting its activation. This selective binding is crucial for its role in modulating cellular processes associated with cancer, making it an essential tool for research in oncology and tumor biology.

Ipilimumab is a fully human monoclonal antibody of the IgG1κ isotype designed to inhibit the cytotoxic T lymphocyte antigen 4 (CTLA-4) receptor on T cells. This antibody is utilized in research focused on unresectable or metastatic melanoma (MM), serving as a critical tool in investigating the modulation of immune checkpoints in cancer therapy.

Simridarlimab is a humanized immunoglobulin (Ig) antibody that specifically targets the CD274 and CD47 antigens. This dual targeting approach enhances the antibody's ability to modulate the immune response against cancer cells, making it a valuable tool in oncological research and therapeutic development.

Imgatuzumab (RG 7160) is a humanized monoclonal antibody specifically targeting the Epidermal Growth Factor Receptor (EGFR). It functions primarily as an immunomodulator. This antibody is utilized in the study of various cancers, providing a valuable tool for researchers exploring the role of EGFR in oncogenic processes and therapeutic interventions.

Iluzanebart is a human monoclonal IgG1 antibody designed as an agonist for human Triggering Receptor Expressed on Myeloid cells 2 (hTREM2). This antibody enhances the survival and functionality of microglia by activating the TREM2 signaling pathway, thereby compensating for deficits in CSF1R (Colony Stimulating Factor 1 Receptor) function. It is specifically developed for use in research related to adult-onset leukoencephalopathy with CSF1R pathology (CSF1R-ALSP), providing a valuable tool for investigating the molecular mechanisms and potential therapeutic targets for this condition.

Tovetumab (MEDI-575) is a monoclonal antibody specifically targeting PDGFRα, designed to inhibit signal transduction pathways mediated by this receptor. This antibody is utilized primarily in the investigation of pathological conditions such as glioblastoma and non-small cell lung cancer (NSCLC), where PDGFRα plays a critical role in disease progression and cellular proliferation. Tovetumab offers a strategic tool for researchers studying the molecular mechanisms and therapeutic interventions related to these cancers.

Mosunetuzumab (BTCT-4465A) is a fully humanized, full-length immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody designed to concurrently target CD20 on B cells and CD3 on T cells. This bispecific nature allows Mosunetuzumab to redirect T cells to engage and eliminate malignant B cells. It is primarily utilized in research focused on relapsed or refractory B-cell non-Hodgkin lymphomas (B-NHLs), providing a valuable tool for studies aimed at understanding and potentially treating these conditions.

The Anti-LILRB4/ILT3/CD85k Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. This antibody specifically targets the LILRB4/ILT3/CD85k antigen, a critical regulatory receptor expressed on the surface of immune cells. With a molecular weight of approximately 144.36 kDa, this antibody serves as a valuable tool for the study of immune checkpoint regulation and potential therapeutic intervention in immune-related disorders.

Gruticibart is a human IgG4 κ monoclonal antibody targeting Factor XI (F11). For experimental control purposes, it is recommended to use Human IgG4 (S228P) kappa as an isotype control. This antibody is specifically designed for the study of coagulation processes and potential therapeutic interventions related to blood clotting disorders.

Cirevetmab (ZTS-00521426) is a caninized monoclonal antibody specifically designed for targeting Canis lupus familiaris TGFB1. Classified as an immunoglobulin G2-kappa, this antibody serves as an immunomodulator, influencing cellular responses and immune regulation in therapeutic applications. Cirevetmab is engineered for high specificity and efficacy in modulating the biological activity of TGFB1, making it an essential tool for research in canine immunological disorders.

Zanidatamab (ZW25) is a humanized, bispecific monoclonal antibody designed to target two distinct epitopes (ECD2 and ECD4) of the human epidermal growth factor receptor 2 (HER2). This antibody exhibits potent anti-tumor activity by engaging these specific regions, enhancing its therapeutic efficacy in oncology research. Zanidatamab is primarily used in studies investigating the treatment of HER2-positive cancers.

Lesabelimab (LDP) is a monoclonal antibody of the immunoglobulin G1-kappa class, specifically targeting CD274, also known as PD-L1. CD274 functions as an immune checkpoint ligand that inhibits antitumor immune responses by engaging the PDCD1 (PD-1) receptor. This interaction is crucial for modulating immune system activity, particularly in the suppression of T-cell mediated immunity in various cancers. Lesabelimab is designed to disrupt this interaction, thereby enhancing the body's antitumor immune response. This antibody is pivotal for research focused on cancer immunotherapy and the study of immune checkpoint pathways.

MOR-8457 is a monoclonal antibody specifically designed to target PDGF-BB, a critical factor implicated in the pathogenesis of liver fibrosis. This antibody is optimized for use in murine models to investigate the molecular mechanisms and potential therapeutic targets for liver fibrosis.

Etalanetug is a humanized IgG1κ monoclonal antibody that selectively targets microtubule-associated protein tau (MAPT). For control experiments, it is recommended to use Human IgG1 kappa as the isotype control. This antibody is designed for the specific detection and study of MAPT's role in various biological processes, making it an essential tool for research in neurodegenerative diseases and other tauopathies.

The Anti-KLK5/Kallikrein 5 Antibody is a recombinant human antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting the KLK5/Kallikrein 5 protease. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, with an approximate molecular weight of 150 kDa. For experimental control purposes, the Human IgG1 kappa, Isotype Control is recommended.

Domvanalimab (AB154) is a humanized monoclonal antibody targeting TIGIT (T cell immunoreceptor with Ig and ITIM domains). This antibody selectively binds to human TIGIT, effectively inhibiting the interaction between TIGIT and its ligand CD155. Domvanalimab is primarily utilized in oncological research to explore the modulation of immune responses against cancer cells. This inhibition potentially enhances T cell activation and NK cell cytotoxicity, offering a promising avenue for cancer immunotherapy studies.

Ligufalimab (AK 117) is a humanized IgG4 monoclonal antibody targeting CD47. This antibody is engineered to avoid the induction of red blood cell (RBC) hemaglutination, while effectively promoting phagocytosis. Ligufalimab has demonstrated significant anti-tumor activity in various models, making it a valuable tool for research in cancer immunotherapy.

Gimsilumab (MORAb-022) is a human monoclonal antibody that targets granulocyte-macrophage colony-stimulating factor (GM-CSF). This antibody exhibits potential for use in research focused on COVID-19 and rheumatoid arthritis (RA), providing a valuable tool for investigating the role of GM-CSF in inflammation and immune response associated with these conditions.

Nivisnebart is a human monoclonal antibody of the IgG1κ subtype that specifically targets SORT1. For experimental control purposes, it is recommended to use Human IgG1 kappa as an isotype control.

Serclutamab is a humanized chimeric monoclonal antibody that specifically targets the epidermal growth factor receptor (EGFR), subclass IgG1-κ. It is produced in Chinese Hamster Ovary (CHO) cells, ensuring high fidelity and stability in its structure. This antibody is designed for use in research studies focused on the biological pathways influenced by EGFR, including cellular proliferation, differentiation, and survival.

Epcoritamab (GEN3013) is a bispecific IgG1 antibody designed to redirect T-cells to target CD3×CD20+ tumor cells. This antibody facilitates potent T-cell-mediated cytotoxicity against B-cell non-Hodgkin lymphoma (NHL) cell lines, offering a targeted approach to cancer immunotherapy.

MDX-1105 is a human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target B7-H1/PD-L1/CD274, a protein implicated in the negative regulation of immune responses. This antibody features a human IgG4SP subtype heavy chain and has a predicted molecular weight of approximately 150 kDa. For experimental control purposes, Human IgG4 kappa, Isotype Control serves as the appropriate isotype control for MDX-1105, ensuring accurate interpretation of results in research applications focused on immunomodulation and cancer immunotherapy.

Pimurutamab is a humanized IgG1-κ monoclonal antibody specifically designed to target the Epidermal Growth Factor Receptor (EGFR). This antibody is produced in CHO-K1 cells, ensuring high fidelity and consistency in performance. Pimurutamab binds to EGFR with high specificity, making it an invaluable tool for research focused on cancer biology and therapeutic development where EGFR plays a critical role.

Dresbuxelimab (AK-119) is an IgG-κ monoclonal antibody specifically designed to target CD73. It is produced using a Chinese Hamster Ovary (CHO) cell expression system. This antibody has potential applications in research focused on the enzymatic activity of CD73 and its role in immunosuppressive pathways, making it a valuable tool for studies in immunology and cancer research.

Icrucumab (IMC-18F1) is a human IgG1 monoclonal antibody that targets VEGFR-1 (FLT1). This antibody exhibits potential utility in the research of advanced solid tumors, providing a critical tool for investigating the role of VEGFR-1 in tumor angiogenesis and progression.

The Anti-ACVR2B Antibody is a human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target the ACVR2B receptor. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, and exhibits a predicted molecular weight of 144.42 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended. This antibody is suitable for a range of research applications focusing on the biological functions and pathophysiological roles of the ACVR2B receptor.

Lumretuzumab is a humanized monoclonal antibody that targets the human epidermal growth factor receptor 3 (HER3 or ERBB3). This recombinant antibody is designed for use in cancer research, facilitating the study of HER3's role in oncogenic signaling pathways and tumor progression. Lumretuzumab's specificity for HER3 makes it a valuable tool for investigating potential therapeutic interventions in HER3-associated malignancies.

Cendakimab (RPC4046; ABT 308; CC-93538) is a humanized, recombinant monoclonal antibody engineered to selectively target the interleukin-13 (IL-13) cytokine. Demonstrating high affinity and potency, this antibody effectively binds to both the wild-type and variant forms of human IL-13. Cendakimab inhibits the interaction of IL-13 with its receptors, IL-13Rα1 and IL-13Rα2, exhibiting half-maximal inhibitory concentrations (IC50s) of 352 pM and 631 pM, respectively, as determined by enzyme-linked immunosorbent assay (ELISA). Furthermore, it exhibits binding affinities of 52 pM for wild-type IL-13 and 50 pM for the R110Q polymorphic variant of IL-13. The therapeutic potential of Cendakimab spans various IL-13-mediated allergic and inflammatory conditions, including asthma and eosinophilic esophagitis.

DX-2647 is a human monoclonal antibody that targets insulin-like growth factor-II (IGF-II), exhibiting potent anti-tumor and anti-proliferative properties. This antibody is specifically designed to bind to IGF-II, thereby inhibiting its interaction with the insulin-like growth factor 1 receptor (IGF-1R) and the insulin receptor (IR), which are critical pathways in cancer cell proliferation and survival. DX-2647 offers a promising therapeutic strategy for the treatment of cancers characterized by elevated levels of IGF-II.

Anti-IL-9 Antibody (MH9A4) is a mouse monoclonal antibody of the IgG2b, κ subclass, specifically designed to target human interleukin-9 (IL-9). This chimeric antibody is engineered for high specificity and affinity in recognizing and binding to IL-9, a cytokine involved in various inflammatory and immune responses. For appropriate experimental controls, it is recommended to use Mouse IgG2b kappa, Isotype Control, which serves as a non-reactive isotype control to help distinguish specific from non-specific binding.

Muromonab is a monoclonal antibody that specifically targets the CD3 receptor on T cells. This antibody effectively blocks cytotoxic T cell activity, serving as a potent immunosuppressive agent. It is primarily used to prevent acute rejection in solid organ transplantation by inhibiting the immune response that can lead to organ rejection.

Milatuzumab (hLL1; MEDI-115) is a humanized monoclonal antibody targeting CD74, an integral membrane protein implicated in the promotion of B-cell growth and survival. This antibody induces the generation of reactive oxygen species and disrupts mitochondrial membrane potential, leading to apoptosis. Additionally, Milatuzumab reduces CD20/CD74 aggregates and cell adhesion, further promoting cell death. This antibody is pivotal for research into the mechanisms of B-cell malignancies and autoimmune diseases, where CD74 plays a key role.

Vatelizumab (GBR500) is a monoclonal antibody specifically designed to target the α2 subunit (CD49b) of very late antigen-2 (VLA-2). This antibody is primarily utilized in the investigation of multiple sclerosis, offering a valuable tool for researchers studying the pathogenesis and potential treatments of this neurological disorder.

The Anti-CD9 Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting the CD9 antigen. This antibody comprises human IgG2 heavy chains and human lambda light chains, with an approximate molecular weight of 145.98 kDa. For isotype control, Human IgG1 kappa, Isotype Control is recommended. This product is ideal for research applications focusing on the role of CD9 in cellular processes and disease mechanisms.

Diridavumab is a monoclonal antibody targeting the HA stalk of the influenza virus. It functions by stabilizing the prefusion conformation of hemagglutinin (HA) and inhibiting the pH-dependent fusion of cellular and viral membranes within endosomes. This antibody is specifically utilized in research focused on the H2 subtype of the influenza virus, providing a valuable tool for studies aimed at understanding viral entry mechanisms and developing therapeutic strategies.

Unasnemab (MT-3921), a humanized IgG1 monoclonal antibody, specifically targets and binds to repulsive guidance molecule A (RGMa). This interaction facilitates the improvement of locomotor functions and promotes neuroregeneration. Unasnemab is primarily utilized in research focused on spinal cord injuries, offering significant insights into therapeutic strategies and recovery mechanisms.

Sulesomab (IMMU-MN3) is a murine monoclonal antibody fragment belonging to the IgG1 class, specifically designed to target Normal Cross-Reactive Antigen-90 (NCA-90) found on leukocytes. This antibody demonstrates enhanced localization to sites of infection, facilitated by its ability to exploit the increased permeability of capillary membranes associated with inflammatory responses. Sulesomab is utilized primarily in research focused on the identification and characterization of leukocyte dynamics during infection and inflammatory processes.

Magrolimab (Hu5F9-G4) is a humanized monoclonal antibody targeting CD47. By inhibiting the CD47-mediated "don't eat me" signal, Magrolimab enhances macrophage-mediated phagocytosis. This antibody demonstrates significant antitumor activity, particularly in the treatment of malignant bone tumors and breast cancer, making it a valuable tool for research in oncology and immunotherapy.

Anti-TCR (NKTT320) is a novel humanized monoclonal antibody that specifically targets the invariant T cell receptor (TCR). This antibody is designed for use in cell-based cancer immunotherapy, offering a targeted approach to modulate the immune system's response against cancerous cells.

PY159 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting TREM1 (Triggering Receptor Expressed on Myeloid cells 1), also known as CD354. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, with a predicted molecular weight of 143.66 kDa. For experimental control purposes, the appropriate isotype control is Human IgG1 kappa.

Opelkibart is a human IgG1 κ monoclonal antibody targeting the KIT receptor. For control experiments, it is recommended to use Human IgG1 kappa as an isotype control.

Nelmastobart is a human IgG4 κ monoclonal antibody targeting BTN1A1. For accurate experimental controls, it is recommended to use Human IgG4 (S228P) kappa as an isotype control.

Negalstobart is a human IgG4 κ monoclonal antibody targeting LAG-3. For control experiments, it is recommended to use Human IgG4 (S228P) kappa as an isotype control.